xaluritamig (AMG 509) / Amgen 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
4 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
xaluritamig (AMG 509) / Amgen
NCT06691984: Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
3
675
NA
Xaluritamig, Abiraterone, Enzalutamide, Cabazitaxel
Amgen
Metastatic Castration-resistant Prostate Cancer
08/28
11/29
NCT06555796: Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer

Recruiting
1
40
US, RoW
Xaluritamig, AMG 509
Amgen
Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer
09/26
03/29
NCT06613100: Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer

Not yet recruiting
1
30
NA
Xaluritamig, AMG 509
Amgen
Prostate Cancer
05/26
09/29
NCT04221542: Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer

Jul 2023 - Dec 2023: Preliminary data from trial for mCRPC
Recruiting
1
461
Europe, Japan, US, RoW
AMG 509, xaluritamig, Abiraterone, Enzalutamide
Amgen
Prostate Cancer
04/26
07/28

Download Options